Testing Brenipatide for Moderate-to-Severe COPD in Adults
Tests brenipatide against placebo in adults with moderate-to-severe chronic obstructive pulmonary disease.
Plain-language title generated from the registry record
Registry title: A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Key facts
- Where
- Ajax, Kelowna, Sherbrooke, Trois-Rivières, and Windsor, CanadaSee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT07759245, who can take part
Where in Canada
- Dynamic Drug AdvancementAjax, CanadaNot yet recruiting
- Kelowna Health and Memory CentreKelowna, CanadaTaking people
- Diex Recherche Inc. Division Sherbrooke EstSherbrooke, CanadaTaking people
- C.I.C. Mauricie inc.Trois-Rivières, CanadaNot yet recruiting
- Dr. Syed Anees Medicine Professional CorporationWindsor, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07759245EU 2026-525480-41-00
- Record updated
- 5 November 2026
- Original description
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.
Inclusion: Have a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD), at least 12 months prior to screening who meet the following criteria:; Current or former smokers with a smoking history of greater than or equal to (≥) 10 pack-years; Moderate-to-severe COPD (post-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)/forced vital capacity (FVC) less than (<) 70 percent (%); Modified Medical Research Council Dyspnea Scale (mMRC-DS) grade ≥2; Exacerbation history of ≥2 moderate or ≥1 severe exacerbations within the year prior to inclusion; Background double therapy [long-acting β₂-agonists (LABA) + long-acting muscarinic antagonists (LAMA)] or triple therapy [inhaled corticosteroids (ICS) + LABA + LAMA)] for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to screening.
Exclusion: Have a known pre-existing, clinically important lung condition other than COPD; Have a current or recent acute, active infection before screening and up to randomization.